How Much Does CJC-1295/Ipamorelin Cost? (2026)

CJC-1295 and ipamorelin are the most commonly stacked growth hormone secretagogue pair in the peptide market, and the pricing search for this combination reflects that popularity. A quick look at the numbers turns up vials under $100 on one side and telehealth programs at several hundred dollars a month on the other. Those numbers describe different products — not cheaper and more expensive versions of the same thing — and the gap between them is built from layers of regulatory complexity, quality assurance, and medical infrastructure that matter more for injectables than for almost any other consumer product category.

This guide breaks down every pricing tier for 2026, explains the regulatory context that makes this combination's legal pathway unusually complicated, and identifies what each price point actually includes and excludes.

The regulatory reality that shapes 2026 pricing

Understanding what CJC-1295/ipamorelin costs in 2026 requires understanding what happened to its legal status over the prior three years, because the regulatory trajectory directly determines which suppliers can operate, what they're selling, and what it costs.

In September 2023, the FDA placed both CJC-1295 and ipamorelin acetate on its Category 2 list under the Section 503A interim compounding policy — the designation the agency uses when it has identified "potential significant safety risks" for bulk drug substances used in compounding.¹ Category 2 status effectively prohibited licensed 503A compounding pharmacies from preparing these peptides.

In September 2024, both peptides' nominations were withdrawn, removing them from the active Category 2 list. However, withdrawal from Category 2 is not the same as authorization for compounding. The next required step — a Pharmacy Compounding Advisory Committee (PCAC) review to add the substances to the authorized 503A bulks list — was conducted for ipamorelin in October 2024 and for CJC-1295 in December 2024. In both cases, the PCAC did not recommend adding the peptides to the 503A bulks list.²

As of September 2026, neither CJC-1295 nor ipamorelin appears on the FDA's authorized 503A bulk drug substances list. Their PCAC review that could restore licensed compounding access is scheduled as part of a second batch of peptides expected in 2027. The result is a regulatory limbo: not banned, not authorized, and not resolved.

Some telehealth providers continue to offer CJC-1295/ipamorelin through channels outside the standard 503A framework. The legal basis for those offerings varies by provider and is worth asking about directly before engaging any program.

Gray-market (research-use-only) pricing

The largest category of CJC-1295/ipamorelin sources operates outside the licensed pharmaceutical system. These vendors sell the peptides labeled "for research use only" or "not for human consumption" with no prescription required and no physician involved. Their prices are lower because the entire regulatory and clinical layer has been removed from the transaction.

• Pre-blended CJC-1295/ipamorelin vials (10 mg combination): $80 to $150 per vial at most established research suppliers
• CJC-1295 (no DAC) sold separately: $50 to $90 per vial depending on quantity and supplier
• Ipamorelin sold separately: $40 to $80 per vial
• Combined monthly cost (gray market, both peptides): approximately $80 to $150 per month at typical protocol volumes

These prices become less straightforward once you examine what they exclude. Third-party purity testing, sterility verification, cold-chain shipping standards, and an independent certificate of analysis are not standard across gray-market suppliers. The FDA has formally documented its concerns about both compounds: CJC-1295 preparations "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities," and ipamorelin acetate preparations "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities."¹

The FDA also noted specific adverse event findings for each compound — which are addressed separately below.

Telehealth and clinic pricing

When CJC-1295 and ipamorelin are provided through a supervised clinical pathway — a physician evaluation, a prescription, and dispensing through a pharmacy with documented quality standards — the economics change substantially.

• Initial telehealth consultation: $100 to $200, typically billed once
• All-inclusive telehealth program (consultation + peptides + supplies): $200 to $500 per month at most platforms; programs average near $250 to $350
• In-person functional medicine or longevity clinic: $400 to $800 per month, often inclusive of body composition monitoring and lab interpretation
• Baseline laboratory work (IGF-1, metabolic panel, hormone panel): $150 to $300, typically billed separately in the first month
• Quarterly follow-up visits: $75 to $150 per visit
• Injection supplies (syringes, swabs, bacteriostatic water): $10 to $25 per month, often bundled

Telehealth platforms have partially standardized this landscape. Many bundle consultation, prescription, and pharmacy dispensing under a single monthly fee, making direct cost comparisons easier. Clinics that itemize each component — consult fee, compound cost, follow-up — can look cheaper at the headline while arriving at a higher total for the same three-month protocol.

CJC-1295/ipamorelin price comparison by source type

What the price gap actually reflects

Purity and independent testing

Pharmaceutical-grade peptide synthesis requires high-performance liquid chromatography (HPLC) analysis to confirm purity — typically 98 percent or above for the active peptide — and mass spectrometry to verify correct molecular structure. For a combination compound like CJC-1295/ipamorelin, each component requires separate characterization. This testing costs money and is reflected in the final price. Gray-market suppliers vary widely in whether they test at all, whether testing is batch-specific, and whether the certificate of analysis is issued by a genuinely independent laboratory. The FDA's concern about "peptide-related impurities" in compounded CJC-1295 and ipamorelin is not abstract — it names the precise gap between gray-market and pharmaceutical-grade production.¹

Sterile manufacturing

Injectable preparations require sterile manufacturing conditions. Pharmacies operating under USP Chapter 797 sterility standards — the baseline for licensed 503A compounding — must maintain cleanroom conditions, conduct regular environmental monitoring, and perform end-product sterility and endotoxin testing. Gray-market operations face no such requirements, and there is no reliable way to verify their manufacturing conditions from the outside. For peptides administered via subcutaneous injection, sterility failures translate directly into infection risk.

Cold-chain shipping

Peptides degrade when exposed to heat. Maintaining temperature between 2°C and 8°C from manufacturer to patient adds $15 to $35 per shipment. Many gray-market vendors ship at ambient temperature or with minimal insulation. A heat-degraded vial looks identical to a properly stored one, and there is no visible indicator of potency loss or structural change after degradation.

Medical oversight

The supervised pathway includes a physician who evaluates whether these compounds are appropriate for a given patient, identifies contraindications, and can monitor for adverse responses. Dr. Anthony C. Tam, MD — a sports medicine physician with Henry Ford Health and team physician for USA Wrestling, USA Cycling, and USA Volleyball — stated in an AMA interview that newer injectable peptides "have not been thoroughly tested or reviewed by the FDA, so we don't have data from trials," and advised that patients consult a physician "who can give you the best information and help you make the wisest decision. We want to find ways to improve your health in the safest ways possible."⁴

The FDA's documented safety findings for each compound

The FDA's review of the evidence for both peptides produced specific adverse event findings that inform the current regulatory uncertainty and should inform any cost-benefit analysis for prospective users.

For CJC-1295, the FDA identified "serious adverse events including increased heart rate and systemic vasodilatory reaction." These cardiovascular effects — flushing, warmth, and transient hypotension — are pharmacologically predictable consequences of a GHRH analog with an unusually long half-life. CJC-1295 was shown in a 2006 Phase I trial in healthy adults to produce a mean plasma growth hormone elevation of 2 to 10 times baseline lasting six or more days from a single injection, with an estimated half-life of 5.8 to 8.1 days — compared with minutes for natural GHRH.³ That longevity is part of the compound's market appeal, and also part of its risk profile: extended half-lives mean extended exposure to any adverse effects.

For ipamorelin acetate, the FDA noted that "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility." The FDA added that it has not identified sufficient safety information for other injectable routes to know whether harm would result.¹

These findings do not establish that either compound is inherently unsafe at subcutaneous doses — they reflect the FDA's determination that available data were insufficient to authorize compounding to proceed. That regulatory determination, not a finding of harm, drives the current access restrictions.

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data." — Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School³

Insurance, HSA, and FSA coverage

Health insurance does not cover CJC-1295 or ipamorelin. Commercial insurance, Medicare, and Medicaid all require FDA approval for coverage, and neither peptide has cleared that threshold for any indication. There is no reimbursement pathway regardless of how either compound is obtained.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) may cover costs when a licensed physician prescribes either peptide for a qualifying medical condition and documents that in a letter of medical necessity. Whether a given plan administrator accepts this depends on the specific plan, the diagnostic documentation provided, and the applicable tax year's rules. Verify with your plan administrator before assuming coverage — and confirm in writing, not verbally.

Budget the full out-of-pocket cost before pursuing CJC-1295 or ipamorelin through any channel.

The realistic total cost of a supervised protocol

Patients comparing gray-market and clinical pricing often underestimate how quickly the supervised pathway's costs accumulate month to month. A realistic first-month accounting for a typical telehealth protocol looks like this:

• Initial consultation: $100 to $200 (one-time, most platforms)
• Baseline laboratory work (IGF-1, metabolic panel, hormone panel): $150 to $300
• Peptide blend, first month: $150 to $300
• Injection supplies: $10 to $25
• Total first month: approximately $410 to $825

Subsequent months are cheaper because the consultation and labs are not repeated monthly. Ongoing costs typically run $150 to $350 per month depending on the platform, dose, and whether follow-up visits are bundled. A realistic 8-week protocol totals $500 to $1,200 in the first month (inclusive of intake) and $150 to $350 per subsequent month if continued.

For comparison, the gray-market alternative runs approximately $80 to $150 per month with no consultation, no lab monitoring, and no quality assurance. Whether the difference represents meaningful value depends entirely on how much weight you assign to pharmaceutical-grade quality, physician oversight, and legal protection — none of which the gray market provides.

CJC-1295/ipamorelin cost versus other GH peptides

Patients researching this combination often consider it alongside other compounds that work through similar mechanisms. The cost comparison is worth understanding:

• Sermorelin: A GHRH analog that was FDA-approved (though manufacturer-discontinued); appears on the 503A authorized bulks list, making it more widely available through licensed pharmacies. Monthly compounded cost typically runs $100 to $200, often lower than CJC-1295 alone.
• Tesamorelin (Egrifta): The only FDA-approved GHRH analog, indicated for HIV-associated lipodystrophy. Retail pricing is substantially higher; compounded access is available through specific authorized channels. Not directly comparable in target population.
• Injectable human growth hormone (HGH): Requires a specific FDA-approved diagnosis (adult GHD, Turner syndrome, etc.). Out-of-pocket cost for off-label compounded preparations typically runs $300 to $600 per month; brand-name FDA-approved HGH without insurance can reach several thousand dollars monthly.
• Ibutamoren (MK-677): An oral GH secretagogue, not a peptide. FDA placed it in Category 2 for 503B compounding in 2022 due to congestive heart failure risk in a clinical trial. Access through licensed channels is also unsettled.

On a per-month cost basis, CJC-1295/ipamorelin through gray-market sources is cheaper than any supervised alternative. Through licensed channels, it is priced similarly to sermorelin-based programs but with significantly more regulatory uncertainty attached to the legal pathway.

Questions to ask before spending anything

If you are seriously considering CJC-1295/ipamorelin through a supervised provider, these questions are worth asking — in writing — before committing:

• What is the specific legal basis for dispensing this combination? Given that neither peptide is currently on the FDA's 503A authorized bulks list, a legitimate provider should be able to explain precisely which regulatory pathway applies to their dispensing model.
• Which pharmacy will prepare it, and what quality certifications does that pharmacy hold? PCAB-accredited or 503B-registered facilities offer documented quality assurance above baseline 503A requirements.
• Can the pharmacy provide batch-specific certificates of analysis from an independent laboratory? Not a generic or facility-issued document — batch-specific, third-party verified.
• What does the quoted price actually include? Consultation, lab work, supplies, and follow-up visits are frequently billed separately. Get an itemized breakdown before you pay anything.
• What are the cancellation and refund terms? Monthly subscription models create ongoing financial commitments. Understand the exit terms before signing up.

What this page cannot tell you

This guide covers pricing and the regulatory landscape. It cannot tell you whether CJC-1295 or ipamorelin is appropriate for your situation, whether the evidence supports their use for your specific concern, or whether the regulatory environment will have changed by the time you read this. Those questions require a conversation with a licensed physician who has access to your medical history and current regulatory guidance.

For the underlying evidence on what these compounds are and what the research actually shows, see our CJC-1295 and ipamorelin evidence review. For the broader framework of what peptides are and how they work, that guide is the right starting point. For a comparison of licensed telehealth providers versus gray-market vendors across all peptides — including the quality and legal distinctions that drive the price gap — see our telehealth vs. research vendors guide. And for the full legality picture, our peptide legality guide covers the 503A compounding framework in detail.